CL2017001438A1 - Antagonistas de miostatina o activina para el tratamiento de sarcopenia - Google Patents

Antagonistas de miostatina o activina para el tratamiento de sarcopenia

Info

Publication number
CL2017001438A1
CL2017001438A1 CL2017001438A CL2017001438A CL2017001438A1 CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1 CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1
Authority
CL
Chile
Prior art keywords
sarcopenia
myostatin
treatment
activin antagonists
activine
Prior art date
Application number
CL2017001438A
Other languages
English (en)
Inventor
Dimitris Papanicolaou
David Glass
Patrick Kortebein
Daniel Rooks
Lloyd B Klickstein
Ronenn Roubenoff
Estelle Trifilieff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024187&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001438A1 publication Critical patent/CL2017001438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA, REGIMEN DE DOSIFICACIÔN Y SUS COMPOSICIONES FARMACÉUTICAS, PARA EL TRATAMIENTO DE SARCOPENIA, EN PARTICULAR, SARCOPENIA RELACIONADA CON IA EDAD. ESPECIALMENTE, SE HALLÓ QUE EL ANTAGONISTA DE MIOSTATINA O ACTIVINA BIMAGRUMAB ERA BENEFICIOSO EN EL TRATAMIENTO DE ADULTOS MAYORES CON SARCOPENIA, CON RESPECTO AL AUMERITO DE IA FUERZA Y FUNCION DEL MÜSCULO ESQUELETICO.</p>
CL2017001438A 2014-12-08 2017-06-07 Antagonistas de miostatina o activina para el tratamiento de sarcopenia CL2017001438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088802P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
CL2017001438A1 true CL2017001438A1 (es) 2018-02-16

Family

ID=55024187

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001438A CL2017001438A1 (es) 2014-12-08 2017-06-07 Antagonistas de miostatina o activina para el tratamiento de sarcopenia

Country Status (17)

Country Link
US (1) US20170260275A1 (es)
EP (1) EP3229907A1 (es)
JP (1) JP2017538701A (es)
KR (1) KR20170094292A (es)
CN (1) CN106999589A (es)
AU (2) AU2015358939A1 (es)
BR (1) BR112017011411A2 (es)
CA (1) CA2969800A1 (es)
CL (1) CL2017001438A1 (es)
IL (1) IL252507A0 (es)
MX (1) MX2017007519A (es)
PH (1) PH12017500965A1 (es)
RU (1) RU2017123880A (es)
SG (1) SG11201704094QA (es)
TN (1) TN2017000217A1 (es)
TW (1) TW201627007A (es)
WO (1) WO2016092439A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK2275443T3 (en) 2008-04-11 2016-02-08 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2889377B1 (en) 2012-08-24 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Fcyriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
TWI831538B (zh) 2014-12-19 2024-02-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
BR112018067813A2 (pt) 2016-03-10 2019-01-15 Acceleron Pharma Inc proteínas de ligação ao receptor de activina tipo 2 e usos do mesmo
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
KR101917794B1 (ko) 2018-05-10 2018-11-13 한국과학기술원 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물
KR101966117B1 (ko) 2018-05-25 2019-04-05 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물
KR102017282B1 (ko) 2019-01-28 2019-09-02 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TWI548647B (zh) * 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
WO2013006437A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
TN2015000448A1 (en) * 2012-06-11 2017-04-06 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses therof
BR112016002198A2 (pt) * 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
TW201622746A (zh) * 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法

Also Published As

Publication number Publication date
EP3229907A1 (en) 2017-10-18
AU2019200082A1 (en) 2019-01-31
SG11201704094QA (en) 2017-06-29
PH12017500965A1 (en) 2017-10-18
MX2017007519A (es) 2017-08-22
TN2017000217A1 (en) 2018-10-19
WO2016092439A1 (en) 2016-06-16
CN106999589A (zh) 2017-08-01
JP2017538701A (ja) 2017-12-28
AU2015358939A1 (en) 2017-06-15
US20170260275A1 (en) 2017-09-14
CA2969800A1 (en) 2016-06-16
BR112017011411A2 (pt) 2018-02-14
RU2017123880A3 (es) 2019-08-29
KR20170094292A (ko) 2017-08-17
RU2017123880A (ru) 2019-01-10
TW201627007A (zh) 2016-08-01
IL252507A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
CL2017001438A1 (es) Antagonistas de miostatina o activina para el tratamiento de sarcopenia
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
CL2016001963A1 (es) Heteroarilos inhibidores de syk
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu&#39;inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu&#39;inhibiteurs de bromodomaines
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
DK3125883T3 (da) Indolderivater til anvendelse i medicin
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
CL2017001718A1 (es) Derivados de glucagón con estabilidad mejorada
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
BR112016023494A2 (pt) método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2017000152A1 (es) Derivados de isoindolinona
CL2016002562A1 (es) Régimen de dosificación de liberación inmediata de moduladores s1p.
TWD174815S (zh) 瓶子
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
BR112017013580A2 (pt) combinações de inibidor de btk e regime de dosagem.